This study aims to preliminarily evaluate the efficacy and safety of GB10 intravitreal (IVT) injection for the treatment of patients with neovascular age-related macular degeneration (nAMD). It consists of two parts, single-ascending-dose escalation (SAD) and multiple-ascending-dose escalation (MAD). In SAD, a single IVT of up to 6 doses will be administered to up to 36 treatment-naïve or previously treated patients with nAMD. If the lowest dose is considered safe without dose-limiting toxicity, escalation will proceed to the next higher dose level. At the end of SAD, the two doses that best balance efficacy and safety will be selected and entered into MAD. In MAD, a single IVT of 2 doses will be administered to 12 treatment-naïve or previously treated patients with nAMD, who will be enrolled across the low- to high-dose levels. After GB10 intervention, the participants will undergo tests to evaluate the PK/PD characteristics of GB10 and ocular and non-ocular safety.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The incidence and severity of ocular adverse events
Timeframe: From enrollment to the end of treatment at 12 weeks
The incidence and severity of non-ocular adverse events
Timeframe: From enrollment to the end of treatment at 12 weeks
(SAD) The change in best corrected visual acuity (BCVA) from baseline after 4 weeks of treatment
Timeframe: From enrollment to the end of treatment at 4 weeks
(MAD) The change in best corrected visual acuity (BCVA) from baseline after 12 weeks of treatment
Timeframe: From enrollment to the end of treatment at 12 weeks